CellaVision AB (publ) (STO:CEVI)

Market Cap	3.66B
Revenue (ttm)	723.22M
Net Income (ttm)	140.72M
Shares Out	23.85M
EPS (ttm)	5.90
PE Ratio	26.00
Forward PE	22.48
Dividend	2.50 (1.63%)
Ex-Dividend Date	May 7, 2025

Volume	14,053
Average Volume	23,568
Open	156.80
Previous Close	153.40
Day's Range	150.60 - 156.80
52-Week Range	148.00 - 302.00
Beta	1.23
RSI	37.76
Earnings Date	Apr 29, 2025

About CellaVision AB

CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides digital hematology microscopy solutions, covering analyzers, instruments; and hardware products include in vitro diagnostics IVD for laboratories; as well as its portfolio includes smear makers, stainers, stains, and staining protocols; DIFF-Line is a hematology lab that handle a smaller amount of daily blood samples and consists three instruments for smearing, staining, and analyzin...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1994
• Employees: 228
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CEVI

Financial Performance

In 2024, CellaVision AB's revenue was 723.22 million, an increase of 6.78% compared to the previous year's 677.29 million. Earnings were 140.72 million, an increase of 7.99%.